




## Funzione polmonare nell'asma grave

Pierachille Santus
University of Milan
Department of Biological and Clinical
Sciences (DIBIC)
Division of Respiratory Diseases
"L. Sacco" University Hospital
ASST Fatebenefratelli Sacco – MILAN,
Italy
pierachille.santus@unimi.it



The small airways were subsequently defined as those airways with an internal diameter less than 2 mm


Scichilone N, Pulm Pharmacol Ther. 2013; Bonini Ther Adv Respir Dis 2015


## Piccole vie aeree: caratteristiche anatomo-fisiologiche

Generazione bronchiale	Diametro (cm)	Area di sezione totale (cm²)	Classif	icazione delle v	ie aeree	Afflusso di sangue
0	1,8	2,54			Trachea	
1	1,2	2,33			Tractica	
2	0,83	2,13				
3	0,56	2,00		Grandi vie	Bronchi	
4	0,45	2,48		aeree (>2mm)		
5	0,35	3,11		uoroo (*211111)		
6	0,28	3,96				
7	0,23	5,10	7		Piccoli bronchi	Circolazione
8	0,186	6,95	Zona di conduzione		FICCOII DI ONCIN	bronchiale
9	0,154	9,56	CONGUETORIC			Si oriornato
10	0,130	13,40				
11	0,109	19,60				
12	0,095	28,80		Piccole vie		
13	0,082	44,50		aeree (<2mm)	Bronchioli	
14	0,074	69,40			DIONCHION	
15	0,066	113,00				
16	0,060	180,00				
17	0,054	300,00				
18	0,050	534,00		Bronchioli	respiratori	
19	0,047	944,00	7			
20	0,045	1600,00	Zona di scambio			Arteriole
21	0,043	3220,00	Scarribio	Dotti o sas	ohi oluoolori	
22	0,041	5880,00		Dotti e sac	chi alveolari	
23	0,041	11800,00				

Clarke SW, Pavia D. Aerosols and the lung. Ed. Butterwoths. 1984

## Small Airways: anatomical and physiological meaning





They are generally located from the eighth generation of airways to the respiratory bronchioles and account for 98.8% of the total lung volume

Jain N. Crit Care 2007; Bonini Ther Adv Respir Dis 2015; Clarke SW, Pavia D. Aerosols and the lung. Ed. Butterwoths. 1984




**CHEST** 


Translating Basic Research Into Clinical Practice


#### **Small Airway Obstruction in COPD**

New Insights Based on Micro-CT Imaging and MRI Imaging

James C. Hogg, MD, PhD; John E. McDonough, PhD; and Masaru Suzuki, MD, PhD










3. Calculation of airway resistance: To determine the airway resistance, it is necessary to know the ratio of alveolar pressure to airflow at the mouth,  $P_A/V$ . The experiments yielded two slopes. First, with the shutter open, the slope  $\dot{V}/P_P$  was measured on the S shaped line from the point of 1 liter per second of inspiratory flow to the point of 1 liter per second of expiratory flow.<sup>8</sup> Second, the slope  $P_A/P_P$  is generated with the shutter closed. The total airway resistance is calculated by taking the ratio of slopes:

$$R = \frac{P_A/P_P}{\dot{V}/P_P}$$

where  $P_A$  is alveolar pressure,  $\dot{V}$  is airflow,  $P_P$  is plethysmograph pressure (the same with shutter open and closed), and R is resistance.








The major determinant of airway resistance is lung volume and age has little effect. The line expresses the

differences in age. A method is suggested for correcting changes in airway resistance for concomitant changes in lung volume during studies on airway resistance. Theoretical considerations

J Clin Invest. 1958 Sep;37(9):1279-85



S. Gonem et al Clinical & Experimental Allergy, 42, 1664-1683




Fig. 4 Schematic illustration of the airway reopening concept. When airways close, opposing airway walls get in contact creating a plug of respiratory tract lining fluid. As the airway walls distend during inspiration, forming a meniscus that finally breaks and generate particles. By permission of the author




Figure: Small airway asthma phenotype

## Panel: Clinical pattern recognition of the small airway asthma phenotype

#### Suboptimum asthma control

- Asthma control questionnaire score higher than 1-5
- · Daytime and night-time symptoms
- Regular use of relievers in response to bronchoconstrictor stimuli
- Oral corticosteroid use with viral exacerbations
- Failure to respond to conventional coarse-particle inhaled corticosteroids and long-acting β-agonists

#### Small airways dysfunction

Normal FEV, in conjunction with any of:

- Reduced FEF<sub>20,75</sub>
- Abnormal airway resistance (R5–R20, R<sub>sw</sub>) or reactance area (AX)
- · Evidence of air trapping (closing volume, residual volume)
- Abnormal ventilation heterogeneity (S<sub>em</sub> and S<sub>ond</sub>)

FEV<sub>3</sub>—forced expiratory volume in 1 s. FEF<sub>mex</sub>—forced mild-expiratory flow between 25% and 75% of forced vital capacity. RS-R20-peripheral always resistance as difference between measurements at 5 Hz and 20 Hz. R<sub>m</sub>—plettysmographic alrway resistance. S<sub>m</sub>—actinar (diffusion) dependent ventilation heterogeneity. S<sub>m</sub>—conductive (convection) ventilation heterogeneity.

Frequency Dependence of Compliance as a Test for Obstruction in the Small Airways

ANN J. WOOLCOCK, N. J. VINCENT, and PETER T. MACKLEM




FIGURE 3  $C_{4yn}(1)$  as a percentage of  $C_{st}(1)$  at different frequencies in four asthmatic subjects (——) and four normal subjects (———) of similar age. The number at the right of each graph is the value obtained for  $R_L$  at the time of the study.


# Persistence of Airway Obstruction and Hyperresponsiveness in Subjects With Asthma Remission\*

Louis-Philippe Boulet, M.D., F.C.C.P.; Helène Turcotte, M.Sc.; and Annie Brochu, M.D.

Table 1-Subjects' Characteristics

	Asthma "in Remission"	Controls
No. of subjects	30 (20M, 10F)	30 (20M, 10F)
Age, yr, mean (range)	32.1 (18 to 61)	31.6 (20 to 67)
Atopy, No. of subjects	28	28
No. of positive responses	8.8 (0 to 20)	7.9 (0 to 20)
Past immunotherapy	10	2
Age at the onset of asthma, yr, mean ± SEM (range)	10.5 ± 1.8 (0 to 33)	_
Duration of symptomatic asthma, yr, mean ± SEM (range)	12.4 ± 1.7 (2 to 33)	_
Duration of remission, yr, mean ± SEM (range)	$9.6 \pm 1.3$ (2 to 25)	-
Family history of asthma	11	10
Family history of atopy	16	21


(Chest 1994; 105:1024-31)



(Chest 1994; 105:1024-31)

Small-airway obstruction, dynamic hyperinflation, and gas trapping despite normal airway sensitivity to methacholine in adults with chronic cough

Nilita Sood, <sup>1,2</sup> Scott E. Turcotte, <sup>1,2</sup> Nastasia V. Wasilewski, <sup>1,2</sup> Thomas Fisher, <sup>1</sup> Taylar Wall, <sup>1</sup> John T. Fisher, <sup>2</sup> and M. Diane Lougheed <sup>1,2</sup>



#### Review article

The role of small airways in monitoring the response to asthma treatment: what is beyond  $FEV_1$ ?

Table 1. Lists of procedures that can be employed to assess small airway dysfunction

Procedure	Advantages	Limitations
NO measurement	High sensitivity for inflammation	Need for validity
Sputum induction	High reproducibility, high sensitivity for inflammation	Need for trained staff, time consuming
Transbronchial biopsies	'Gold standard'	Invasive
HRCT	High reproducibility	Side-effects, costs
Spirometry	Simplicity, high reproducibility	Poor correlation to severity
Oscillometry	Simplicity	Poor correlation to severity
Mch bronchoprovocation	High reproducibility, high sensitivity for diagnosis	Poor correlation to severity, time consuming
N2 wash-out	High reproducibility, high sensitivity for diagnosis	Need for trained staff
Asthma questionnaires, diary cards	High reliability, simplicity	Patient dependent

NO, nitric oxide; HRCT, high resolution computed tomography, Mch, methacholine; N2, nitrogen.

#### REVIEW ARTICLE

## Treatment of the bronchial tree from beginning to end: targeting small airway inflammation in asthma

M. van den Berge<sup>1,2</sup>, N. H. T. ten Hacken<sup>1,2</sup>, E. van der Wiel<sup>1,2</sup> & D. S. Postma<sup>1,2</sup>

Table 1 Examples of studies showing an association between small airway disease and the presence and activity of asthma

Reference	Main findings
Wagner et al. (4)	Sevenfold increased peripheral airway resistance measured with the wedged bronchoscope technique in asthma
	vs healthy controls
	Baseline peripheral airway resistance correlates with bronchial hyper-responsiveness to methacholine
Kraft et al. (5)	Higher peripheral airway resistance at night than during daytime in nocturnal asthma
Kaminsky et al. (6)	Higher peripheral airway resistance correlates with exercise-induced bronchoconstriction
Zeidler et al. (7)	Natural cat allergen exposure increases both methacholine-induced air trapping on HRCT and closing volume measured with the single-breath nitrogen test 6 and 23 h later
1 (1) (1)	
In 't Veen et al. (8)	Asthma patients who have frequent exacerbations (≥2 per year) have a higher degree of small airway disease
	measured with the single-breath nitrogen washout test than patients with infrequent exacerbations (<2 per year)
	whereas their FEV <sub>1</sub> and FEV <sub>1</sub> /FVC are similar
Lee et al. (9)	A higher drop in FVC during PD <sub>20</sub> methacholine is associated with more severe asthma

FVC, forced vital capacity; HRCT, high-resolution computed tomography.

Table 2 Overview of tests for small airway obstruction

	Ability to detect small airway abnormalities	Reproducibility	Advantages	Disadvantages
Table 2 (continued)				**
	Ability to detect small airway abnormalities	Reproducibility	Advantages	Disadvantages
Alveolar and bronchial NO	Alveolar NO related to:  RV/TLC and closing volume in severe asthma (27)  Ventilation heterogeneity in stable asthma (77)  Bronchial NO related to:  Air trapping (CT)	Fair	Noninvasive	<ul> <li>Relatively time-consuming (20 min)</li> <li>Influenced by smoking, caffeine, diet</li> </ul>
Small-particle AMP provocation	Closely related to:  Treatment response to small-particle aerosol (ciclesonide) (56)	Unknown	<ul> <li>Noninvasive</li> <li>Promising new tool to investigate small airway inflammation</li> </ul>	<ul> <li>Bronchial challenge test, relatively time-consuming</li> <li>Little evidence</li> </ul>
Late-phase sputum induction	<ul> <li>The concentration of surfactant protein         A was significantly higher in a late-vs         early-phase sputum, suggesting sampling of         the more distal airways (78)</li> <li>Small-particle HFA-beclomethasone, but not         large-particle DPI-budesonide, significantly reduced         the percentage of eosinophils and expression of         IL-4 and IL-5 mRNA in late-phase sputum</li> </ul>	Unknown	Noninvasive	High costs     Little evidence
Transbronchial biopsies	<ul> <li>The number of transbronchial biopsy eosinophils was found to be associated with TLC and FRC, but not with FEF<sub>25-75</sub> or FVC Unfortunately, no data on RV/TLC were presented (79)</li> </ul>	Unknown	Direct measurement of small airway inflammation and remodeling	<ul> <li>Invasive</li> <li>Few studies available on the association between markers of inflammation and/or remodeling in transbronchial biopsies and other parameters of small airway inflammation and/or dysfunction</li> </ul>

Adapted with permission from reference (1). FVC, forced vital capacity; CT, computed tomography; MCh, methacholine; FEV<sub>1</sub>, forced expiratory volume in 1-s; PC<sub>20</sub>, provocative concentration causing the FEV<sub>1</sub> to drop with 20%; FEF<sub>25-75</sub>, forced expiratory flow between 25% and 75% of the FVC; NO, nitric oxide; RV, residual volume; TLC, total lung capacity; SBNW, single-breath nitrogen washout test; MBNW, multiple-breath nitrogen washout test; AMP, adenosine 5'-monophosphate; IL, interleukin; FRC, functional residual capacity; DPI, dry powder inhaler; FOT, forced oscillometry.

	Ability to detect small airway abnormalities	Reproducibility	Advantages	Disadvantages
ΔFVC at PC <sub>20</sub>	Closely related to:  Disease severity (10)  MCh-induced air trapping (CT)  Maximal airway response to MCh (11)	Good	Noninvasive     Easy to perform     Widely available	Bronchial challenge test, time-consuming     High costs     Performing complete FVC maneuve twice at each dose is strenuous
FVC/SVC	Detects and monitors small airway disease in BOS after lung transplantation (72)	Poor	Noninvasive     Easy to perform     Low costs     Not time-consuming	<ul> <li>Not a very specific test for the measurement of small airway disease</li> </ul>
FEF <sub>25-76</sub>	Closely related to: • Air trapping (CT) (73) • FEF <sub>25-75</sub> is often normal when FEV₁/FVC ≥ 75% (74)	Poor	Noninvasive     Easy to perform     Low costs     Not time-consuming	Not a very specific test for the measurement of small airway disease Wide range of normal Dependence on FVC
IOS or FOT	FEF <sub>25-75</sub> (75)     Methacholine (MCh)-induced changes in vestilation Meteococcepts (75).	Fair	Noninvasive     Easy to perform     Low costs     Not time-consuming	<ul> <li>Not a very specific test for the measurement of small airway disease</li> </ul>
SBNW: closing volume	Closely related to:Alveolar NO in severe asthma (27)	Fair	Noninvasive     Relatively low costs     Not time-consuming	Difficult measurement to perform without flow restrictor     High variability     Lack of certainty about interpretation
MBNW	Closely related to:  • Alveolar NO (77)	Good	Noninvasive     Easy to perform	Not widely available     High costs     Lack of certainty about interpretation
(MCh-induced) air trapping with CT	Closely related to:  • ΔFVC at PC <sub>20</sub> • High costs • RV/TLC (33)	Good	<ul> <li>Noninvasive</li> <li>Direct visualization of air trapping, which may reflect small airway disease</li> </ul>	<ul> <li>Radiation load is unfavorable</li> <li>High costs</li> <li>Time-consuming (approximately 70 min including MCh challenge)</li> </ul>
RV/TLC	N Alveolar NO in severe asthma (27)     Air trapping (CT) (33, 73)	Fair	Noninvasive	Relatively time-consuming (30 min)

## The Relations between Structural Changes in Small Airways and Pulmonary-Function Tests

M. Cosio, M.D., H. Ghezzo, M.S.C., J. C. Hogg, M.D., R. Corbin, M.D., M. Loveland, M.D., J. Dosman, M.D., and P. T. Macklem, M.D.et al.


June 8, 1978


N Engl J Med 1978; 298:1277-1281


DOI: 10.1056/NEJM197806082982303

#### Abstract

To examine the relation between small-airways abnormalities and specific lung functions, we performed pulmonary-function tests in 36 patients, of whom two were nonsmokers, one to three days before open-lung biopsy for localized pulmonary lesions. The primary lesion in the small airways was a progressive inflammatory reaction leading to fibrosis with connective-tissue deposition in the airway walls. Increase in disease in small airways correlated with deterioration in lung function. Lesions could be reliably detected (P<0.05) by tests for closing capacity, the volume at which air and helium flow were equal (a test of airway caliber and elastic recoil), and the slope of phase III of the single-breath washout curve (which tests evenness of ventilation). These tests showed abnormalities at a time when the pathologic changes were still potentially reversible and when other tests were not appreciably changed. (N Engl J Med 298:1277-1281, 1977)







Airway occlusion assessed by single breath N<sub>2</sub> test and lung P-V curve in healthy subjects and COPD patients

Matteo Pecchiaria, Dejan Radovanovich, Pierachille Santush, Edgardo D'Angeloa, e


Respiratory Physiology & Neurobiology 234 (2016) 60-68

Furthermore, in these patients airway closure involves a substantially greater fraction of the resting tidal volume; consequently, cyclic opening and closing should cause greater damage as it affects already altered airways.

#### RESEARCH ARTICLE

Acute effects of long-acting bronchodilators on small airways detected in COPD patients by single-breath N<sub>2</sub> test and lung P-V curve

Matteo Pecchiari, Pierachille Santus, Dejan Radovanovic, and Edgardo D'Angelo





Bronchodilation improves the closing volume at every point of PL<PL,cv

Significantly improvment of CVexp/VC and CVexp/TLC

None critical closing pressure modification

The central point related all these changes is the reduction of **ITGV** and **RV** and the improvement of **ERV** 





doi: 10.1111/cea.12257

ORIGINAL ARTICLE Asthma and Rhinitis

Clinical & Experimental Allergy, 44, 499-507
© 2013 John Wiley & Sons Ltd

	Healthy controls (n = 18)	Mild-moderate asthma $^{\dagger}(n = 43)$	Severe asthma <sup>†</sup> $(n = 31)$
Age (years)	48.3 (3.9)	57.2 (2.0)	53.8 (2.5)
Sex (% male)	50	51	39
BMI (kg/m <sup>2</sup> )	26.8 (1.2)	27.0 (0.8)	30.0 (1.4)
Atopy (% atopic)	-	79	71
Duration of	-	18.7 (2.9)	25.3 (3.2)
asthma (years)			
Age of onset of	_	38.4 (3.3)	28.3 (3.8)
asthma (years)*			
ICS dose (BDP		547 (66)	1726 (118)
equivalent [mcg])****			
Oral prednisolone use (%)****	-	0	45
Leukotriene receptor	-	5	35
antagonist use (%)**			
Oral theophylline	-	0	19
use (%)**			
Exacerbations in	-	1.0 (0.28)	3.5 (0.56)
past year			
ACQ-6 score***	1 1	0.99 (0.12)	1.82 (0.22)
AQLQ(S) score*	- Transport	5.65 (0.16)	5.00 (0.23)
FEV: (% pred.) ***	113.3 (4.8)	90.8 (3.4)	86.9 (4.6)
FVC (% pred.)*	117.2 (5.6)	101.1 (3.0)	105.0 (4.2)
FEV, FVC (%)***	80.7 (1.0)	73.1 (1.5)	68.4 (2.2)
TLC (L)	6.39 (0.37)	6.14 (0.21)	6.00 (0.30)
TLC (% pred.)	104.3 (3.9)	104.9 (2.5)	107.8 (3.2)
RV/II.C (% pred.)***	89.2 (3.2)	110.4 (3.1)	108.7 (2.7)
VA (L)	5.58 (0.34)	5.07 (0.22)	4.88 (0.27)
VA/ILC (%)**	90.3 (1.7)	82.0 (1.6)	80.8 (1.4)
OLco (% pred.)	89.3 (2.9)	91.2 (2.5)	89.5 (2.9)
Koo (% pred.)	97.4 (2.9)	107.4 (2.7)	104.6 (3.0)
FRC <sub>mbw</sub> (L)	2.52 (0.19)	2.45 (0.11)	2.39 (0.17)
.cı	7.28 (0.27)	7.79 (0.20)	7.94 (0.22)
Scond (L-1)	0.033 (0.007)	0.051 (0.006)	0.038 (0.005)
Sacin (L-1)	0.118 (0.014)	0.175 (0.019)	0.184 (0.020)
R5 (kPa L <sup>-1</sup> s)***	0.32 (0.03)	0.37 (0.02)	0.47 (0.03)*
R20 (kPa L <sup>-1</sup> s)***	0.29 (0.02)	0.31 (0.01)	0.39 (0.02)**
R5-R20 (kPaL <sup>-1</sup> s) <sup>‡</sup> *	0.03 (0.01-0.06)	0.05 (0.03-0.11)	0.05 (0.01-0.1
K5 (kPa L <sup>-1</sup> s)	-0.10 (0.01)	-0.13 (0.01)	-0.15 (0.02)
AX (kPa L <sup>-1</sup> )**	0.23 (0.16-0.54)	0.41 (0.24-0.66)	0.47 (0.23-1.2

Table 3. Correlations between clinical outcome measures and physiological variables

	ACQ-6 score	AQLQ(S) score	FEV <sub>1</sub> (% pred.)
FEV <sub>1</sub> (% pred.)	-0.285*	0.289*	_
FVC (% pred.)	-0.230	0.299*	0.835**
FEV <sub>1</sub> /FVC	-0.166	0.100	0.657**
TLC	-0.252*	0.254*	0.100

Table 4. Linear regression models assessing the contributions of physiological variables to ACQ-6 and AQLQ(S) scores

Dependent variable	Constant term	Independent variables		ndardized ficient (B)	Standardized coefficient (β)	P-value	Model R <sup>2</sup>
ACQ-6 score	1.129	R20 (kPa L <sup>-1</sup> s)	3.2	76	0.330	0.005	0.187
		FEV <sub>1</sub> (% pred.)	-0.0	10	-0.229	0.046	
AQLQ(S) score	5.459	R20 (kPa L <sup>-1</sup> s)	-4.3	55	-0.398	< 0.0005	0.229
		FVC (% pred.)	0.0	14	0.248	0.026	
	R5	0.341**	-0.405**	-0.340**			
	R20	0.369**	-0.430**	-0.169			
	log R5-R20	0.221	-0.250*	-0.379**			
	X5	-0.070	0.091	0.402**			
	log AX	0.173	-0.202	-0.492**			

ACQ-6, Six-point Asthma Control Questionnaire; AQLQ(S), standardized Asthma Quality of Life Questionnaire; FEV<sub>1</sub>, forced expiratory volume in one second; FVC, forced vital capacity; TLC, total lung capacity; RV, residual volume; VA, alveolar volume (single-breath helium dilution); DLco, diffusing capacity of the lung for carbon monoxide; Kco, carbon monoxide transfer coefficient; FRC<sub>mbw</sub>functional residual capacity from multiple breath washout; LCI, lung clearance index; R5/R20, resistance at 5 Hz/20 Hz; R5-R20, resistance at 5 Hz minus resistance at 20 Hz; X5, reactance at 5 Hz; AX, reactance area. Pearson's correlation coefficients are shown. Significant correlations are indicated \* $\{P < 0.05\}$  or \*\* $\{P < 0.01\}$ .

Monitoring the Temporal Changes of Respiratory Resistance: A Novel Test for the Management of Asthma




Figure 1. (Left panel) Long-term variability of the Rinsp characterized by the coefficient of variation (CVRINSP) of individual subjects measured in the morning in individual subjects with asthma (solid symbols) and healthy subjects (open symbols) plotted against time windows. (Right panel) conditional probability computed on an individual basis that a given CV<sub>RINSP</sub> calculated over the past 8 days is associated with an increase in Rinsp greater than or equal to twice the predicted respiratory resistance within the next week. Each point of the prediction curve is the average probability of an interval centered on that point.

## Overall and peripheral lung function assessment by spirometry and forced oscillation technique in relation to asthma diagnosis and control




TABLE 3 Odds ratio (OR) for uncontrolled asthma, and AUC from ROC analysis for standardized lung function variables

Asthma control, n = 234	OR univariate analysis	AUC univar. analysis	OR multivariate <sup>a</sup> analysis	AUC multivar. analysis
Age, height, weight, sex				0.66
FEV <sub>1</sub>	0.50 (0.31, 0.79)	0.66	0.62 (0.35,1.09)	0.69
FVC	0.75 (0.53, 1.06)	0.60	1.17 (0.64, 2.14)	0.65
FEV <sub>1</sub> /FVC	0.67 (0.48, 0.93)	0.62	0.58 (0.40, 0.84)	0.71
FEF <sub>50</sub>	0.58 (0.39, 0.85)	0.51	0.66 (0.42, 1.03)	0.68
R5	1.32 (0.98, 1.78)	0.58	1.35 (0.93, 1.95)	0.68
R19 <sup>b</sup>	1.36 (0.96, 1.93)	0.60	1.22 (0.81, 1.84)	0.71
X5	0.68 (0.51, 0.91)	0.61	0.69 (0.49, 0.97)	0.69
f <sub>res</sub> b	1.38 (1.04, 1.82)	0.59	1.41 (1.02, 1.95)	0.72
R5-R19 <sup>b</sup>	1.53 (1.12, 2.09)	0.61	1.57 (1.05, 2.35)	0.72
۰		Resolution of the second of th	Ţ	
UCA C			UCA CA UCA CA	ۻ

FIGURE 3 Overall lung function (top) and lung function variables reflecting peripheral airways (bottom) in uncontrolled (UCA) and controlled (CA) asthmatic subjects. The left part shows results from spirometry and the right part from FOT. Data presented as mean values  $\pm SD$ 

# Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study

Dirkje S Postma, Chris Brightling, Simonetta Baldi, MaartenVan den Berge, Leonardo M Fabbri, Alessandra Gagnatelli, Alberto Papi, Thys Van der Molen, Klaus F Rabe, Salman Siddiqui, Dave Singh, Gabriele Nicolini, Monica Kraft, on behalf of the ATLANTIS study group

0-29 <0-001 Predicted Surset (n=382)  0-14 0-001 Decrease in FVC (n=497)	e0-001 Predicted AX (n=520) 0-27 e0-001 Body-mass index (n=764) 0-14 0-002 Predicted decrease in FVC (n=495)	0-001 RV/TLC (n=737) 0-25 -0-001 Predicted raw (n=670) 0-12 0-001 FRC (n=728)	0-001 Reversibility (n=762) 0-24 <0-001 Age (n=764) 0-11 0-002 Eosinophils (n=758)	0-001 Predicted RV/TILC (n=737) 0-22 <0-001 Raw (n=670) 0-11 0-002 Neutrophils (n=759)	0-001 Surret (n=382) 0-20 <0-001 Predicted FRC (n=728) 0-11 0-008 Predicted XS (n=595)	0-10 0-008 Predicted TLC	0-001 R20 (n=629)  0-18 <0-001 Number of exacerbations (n=764) 0-09 0-009 Lymphocytes (n=758)	(n=764) 0-09 0-011	vo.001 Predicted RV (n=693)  0-17 0-023  Duration of smoking (n=182)  0-08 0-028  Number of unscheduled	R5-R20 (n=611) 0-08 0-032 Heart rat
c0-001  Predicted Scaret (n= 382)  0-14 0-001  Decrease in FVC (n=497)	e0-001  Body-mass index (n=764)  0-14 0-002  Predicted decrease in PVC	<0-001 Predicted raw (n=670)  0-12 0-001 FRC	<0-001 Age (n=764) 0-11 0-002 Eosinophils	<0-001  Raw (n=670)  0-11 0-002  Neutrophils	<0-001 Predicted FRC (n=728)  0-11 0-008 Predicted XS	«0-001 ACQ-6 score (n=764) 0-10 0-008 Predicted TLC	vo-001  Number of exacerbations (n=764)  0-09 0-009  Lymphocytes	v0-001 Diastolic blood pressure (n=764) 0-09 0-011 Monocytes	0-023  Duration of smoking (n=182)  0-08 0-028  Number of	<0-001 Predicted R5-R20 (n=611)  0-08 0-032 Heart rat
S <sub>tored</sub> (n=382)  0.14 0-001  Decrease in FVC (n=497)	Body-mass index (n=764) 0-14 0-002 Predicted decrease in PVC	0-12 0-001 FRC	0-11 0-002 Eosinophils	0-11 0-002 Neutrophils	FRC (n=728) 0-11 0-008 Predicted XS	o-10 0-008 Predicted	of exacerbations (n=764)  0-09 0-009 Lymphocytes	blood pressure (n=764) 0-09 0-011 Monocytes	o-o8 0-028 Number of	R5-R20 (n=611) 0-08 0-032 Heart rat
0-001 Decrease in FVC (n=497)	0-002 Predicted decrease in FVC	0-001 FRC	0-002 Eosinophils	0-002 Neutrophils	0-008 Predicted X5	0-008 Predicted TLC	0-009 Lymphocytes	0-011 Monocytes	0-028 Number of	0-032 Heart rat
in FVC (n=497)	decrease in FVC				X5	TLC				Heart rat
					(11-333)	(n=739)			consultations (n=764)	
0-01 0-794	-0-03 0-378	-0-08 0-024	-0-12 0-001	-0-12 0-025	-0-15 <0-001	-0-20 <0-001	-0-22 <0-001	-0-23 <0-001	-0-24 <0-001	-0·25 <0·001
f Exhaled s nitric oxide (n=624)	TLC (n=739)	Age at first diagnosis (n=760)	Mini AQLQ score (n=763)	PC <sub>20</sub> (n=372)	Height (n=764)	EuroQol- 5D-5L score (n=761)	ACT score (n=763)	Predicted sGaw (n=578)	sGaw (n=578)	PD <sub>20</sub> (n=182)
-0-35 <0-001	-0-41 <0-001	-0-55 -0-001	-0-57 <0-001	-0-57 <0-001	-0-60 -0-001	-0-60 <0-001	-0-61 <0-001	-0-62 <0-001	-0-64 <0-001	-0.78 -0.001
FVC (n=762)	Predicted FVC (n=762)	FEV <sub>1</sub> (n=763)	Predicted FEV,/FVC (n=761)	FEV_/FVC (n=761)	FEF <sub>25-75</sub> (n=723)	Predicted FEF <sub>25-75</sub> (n=723)	FEF <sub>90</sub> (n=716)	Predicted FEF <sub>50</sub> (n=716)	Predicted FEV <sub>1</sub> (n=758)	X5 (n=595)
5	-0-35	-0-35 -0-41 -0-001 -0-001 FVC Predicted (n=762) FVC (n=762)	initric oxide (n=739) diagnosis (n=760)  -0-35	nitric oxide (n=739)   diagnosis (n=760)   score (n=763)	initric oxide (n=739) diagnosis (n=763) (n=372)  -0-35	initric oxide (n=739) diagnosis (n=760) (n=372) (n=764)  -0-35	nitric oxide (n=739)   diagnosis   score (n=764)   (n=764)   SD-5L score (n=761)    -0-35	initric oxide (n=739) diagnosis (n=760) (n=763) (n=764) 5D-5L score (n=763) (n=764) (n=764) 5D-5L score (n=763) (n=763) (n=764) 5D-5L score (n=764	nitric oxide (n=739)   diagnosis (n=760)   (n=763)   (n=372)   (n=764)   5D-5L score (n=763)   sGaw (n=578)    -0-35	initric oxide (n=739) diagnosis (n=760) (n=763) (n=372) (n=764) 5D-5L score (n=763) sGaw (n=578) (n=57

Figure 4: Correlations between the clinical SAD score of participants with asthma and all variables measured

ACQ-6=Asthma Control Questionnaire-6. AQLQ=asthma quality of life questionnaire. AX=area of reactance. Decrease in FVC=percentage decrease in FVC from baseline at PC<sub>20</sub> or PD<sub>20</sub>. FEF<sub>20,75</sub>=forced expiratory flow at 25-75% of FVC. FEF<sub>30</sub>=forced expiratory flow at 50% of FVC. FRC=functional residual capacity. FVC=forced vital capacity. IVC=inspiratory reserve volume. PC<sub>20</sub>=provocative concentration that causes a 20% decrease in FEV, from baseline during methacholine challenge. PD<sub>20</sub>=provocative dose that causes a 20% decrease in FEV, from baseline during methacholine challenge. Predicted=values presented as a percentage of predicted=values. RS=ainway resistance at 5 Hz. R20=ainway resistance at 20 Hz. Raw=ainway resistance. RV=residual volume. S<sub>200</sub>\*VT=ventilation heterogeneity of the acinar zone of the lungs. S<sub>200</sub>\*VT=ventilation heterogeneity in the conductive zone of the lungs. S<sub>200</sub>\*VT=ventilation heterogeneity in the conductive zone of the lungs. S<sub>200</sub>\*VT=ventilation heterogeneity. XS=reactance at 5 Hz.

### The Physiology of Small Airways

PETER T. MACKLEM

In asthma, the involvement of airways from the glottis to the alveolar ducts is likely, and the site of this involvement determines the resulting pathophysiology. The small airways of less than 2 mm in diameter are pathways of low resistance and normally contribute about 10% of the total resistance to flow (1, 2). They are reportedly more resistant in the first few years of life (3), but experiments showing this have not been repeated, so that idea has neither been confirmed nor denied. Confirmation of these results would be an important advance, because if the small airways are high-resistance pathways in infancy, then bronchiolitis would be a much more serious condition in infants than in adults. Hogg and colleagues claimed that this was the reason that acute bronchiolitis was a serious disease in infants but apparently not in adults (3). If one-half of all small airways became completely obstructed, their combined resistance would double. However, the large airways would remain unobstructed and their resistance would not change. If small-airway resistance is only 10% of the total, doubling it would only increase total resistance by 10%. Thus it is difficult to detect small airway obstruction by the usual lung function tests.

#### SMALL AIRWAY DISEASE ASSESSMENT

